Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB WOBURN, Mass. , May 14, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, prnewswire.com prnewswire.com / feeds prnewswire-com-financial-services .. prnewswire-com-news-releases / / #money / / 16 days 16d Share
